The Patent Finder

Terms ending in 2040

Codiak Biosciences, Inc.

Every in-force patent on Codiak Biosciences, Inc.'s record whose computed term ends in 2040, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleHolderStatusExpiresConfidence
US 11,992,527Extracellular Vesicles for Vaccine Delivery
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
US 12,502,427Extracellular Vesicles for Vaccine Delivery
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
US 12,766,110Extracellular Vesicles Comprising Sting-Agonist
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
US 12,465,875Process for Preparing Extracellular Vesicles
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
US 12,622,876Methods of Suppressing Delivery of Exosomes to Liver and Spleen
In force
 · High confidence
Lonza Sales AGIn forceHigh confidence
5 of 5 patents shown. Soonest term end first, then patent number.
3 of these are in force and held by Codiak Biosciences, Inc..
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited